Evotec Rises on Boehringer Ingelheim Milestone Payment

Evotec AG (EVT) rose the most in almost two weeks after saying it received a payment of 1.5 million euros ($1.93 million) for achieving a research milestone under an agreement with Boehringer Ingelheim GmbH.

Evotec increased as much as 5.3 percent to 2.62 euros, the biggest intraday gain since June 25, and was trading 3 percent higher at 1:49 p.m. in Frankfurt, giving the Hamburg-based company a market value of 303.8 million euros.

A pain treatment that Evotec is working on for Boehringer Ingelheim has reached the preclinical development phase, the company said today in a statement. The milestone, reached in June, represents an “important transition,” Chief Operating Officer Mario Polywka said today in a statement.

Evotec has had a drug-discovery alliance with Boehringer Ingelheim since 2004 and has produced 18 milestones so far, it said today. The company has shifted its business focus to very early-stage development, shuttling prospective treatments from academic research to pharmaceutical companies, and drug-development services, away from finding and marketing its own products.

To contact the reporter on this story: Weixin Zha in Frankfurt at wzha2@bloomberg.net

To contact the editor responsible for this story: Angela Cullen at acullen8@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.